Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis

Autoimmunity Reviews

Volumn 13, Issue 3, 2014, Pages 281-291

  Arnaud, Laurent ^a,b,c   Mathian, Alexis ^a,b,c   Ruffatti, Amelia ^d   Erkan, Doruk ^e   Tektonidou, Maria ^f   Cervera, Ricard ^g   Forastiero, Ricardo ^h   Pengo, Vittorio ^d   Lambert, Marc ⁱ   Martinez Zamora, Maria Angeles ^j   Balasch, Juan ^j   Zuily, Stephane ^k   Wahl, Denis ^k   Amoura, Zahir ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF PADOVA   (Italy)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g UNIVERSITY OF BARCELONA   (Spain)

^h FAVALORO UNIVERSITY   (Argentina)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF BARCELONA   (Spain)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Antiphospholipid antibodies; Aspirin; Meta analysis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; META ANALYSIS; PATHOGENESIS; PRIMARY PREVENTION; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID ANTIBODIES; ASPIRIN; META-ANALYSIS; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; HEMORRHAGE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; THROMBOSIS;

EID: 84891742650     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.10.014     Document Type: Review

References (51)

1. Staub H.L., Dal Ben E.R., Bauer M.E. The antiphospholipid syndrome and Tregs. Autoimmun Rev 2013 Aug 31, 10.1016/j.autrev.2013.08.004.
2. Mahler M., Norman G.L., Meroni P.L., et al. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
3. Ruiz-Irastorza G., Crowther M., Branch W., et al. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
4. Pierangeli S.S., Favaloro E.J., Lakos G., et al. Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on antiphospholipid antibodies. Clin Chim Acta 2011, 413:358-360.
5. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
6. Tozzoli R., Villalta D. Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev 2014 Jan 13, 13(1):59-63.
7. Pengo V., Banzato A., Denas G., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
8. Roggenbuck D., Egerer K., von Landenberg P., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev 2012, 11:821-826.
9. Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011, 20:206-218.
10. Staub H.L., Bertolaccini M.L., Khamashta M.A. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012, 12:230-234.
11. Galarza-Maldonado C., Kourilovitch M.R., Perez-Fernandez O.M., et al. Obstetric antiphospholipid syndrome. Autoimmun Rev 2012, 11:288-295.
12. Pengo V., Ruiz-Irastorza G., Denas G., et al. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev 2012, 11:577-580.
13. Ceccarelli F., Chighizola C., Finazzi G., et al. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "pros" and "cons". Autoimmun Rev 2012, 11:568-571.
14. Berger J.S., Krantz M.J., Kittelson J.M., et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009, 301:1909-1919.
15. Becattini C., Agnelli G., Schenone A., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012, 366:1959-1967.
16. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
17. Forastiero R., Martinuzzo M., Pombo G., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005, 3:1231-1238.
18. Hereng T., Lambert M., Hachulla E., et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008, 17:11-15.
19. Cervera R., Khamashta M.A., Shoenfeld Y., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009, 68:1428-1432.
20. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C., et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560-1567.
21. Brandt J.T., Triplett D.A., Alving B., et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995, 74:1185-1190.
22. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
23. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
24. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
25. Ruffatti A., Del Ross T., Ciprian M., et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011, 70:1083-1086.
26. Ruffatti A., Del Ross T., Ciprian M., et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009, 68:397-399.
27. Tarr T., Lakos G., Bhattoa H.P., et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007, 16:39-45.
28. Tarr T., Lakos G., Bhattoa H.P., et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol 2007, 32:131-137.
29. Pengo V., Ruffatti A., Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
30. Wahl D.G., Guillemin F., de Maistre E., et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997, 6:467-473.
31. Wahl D.G., Guillemin F., de Maistre E., et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998, 7:15-22.
32. Zuily S., Regnault V., Selton-Suty C., et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2012, 124:215-224.
33. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
34. Erkan D., Harrison M.J., Levy R., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007, 56:2382-2391.
35. Erkan D., Merrill J.T., Yazici Y., et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001, 44:1466-1467.
36. Martinez-Zamora M.A., Cervera R., Balasch J. Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease. Clin Rev Allergy Immunol 2012, 43(3):265-274.
37. Tektonidou M.G., Laskari K., Panagiotakos D.B., et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009, 61:29-36.
38. Erkan D., Yazici Y., Peterson M.G., et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:924-929.
39. Ginsburg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997-1002.
40. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68:238-241.
41. Mok M.Y., Chan E.Y., Fong D.Y., et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005, 32:622-628.
42. Shah N.M., Khamashta M.A., Atsumi T., et al. Outcome of patients with anticardiolipin antibodies: a 10year follow-up of 52 patients. Lupus 1998, 7:3-6.
43. Tincani A., Taglietti M., Biasini C., et al. Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: comment on the article by Erkan et al. Arthritis Rheum 2002, 46:1126-1127. [author reply 1127].
44. Wahl D.G., Bounameaux H., de Moerloose P., et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000, 160:2042-2048.
45. Reiner P., Galanaud D., Leroux G., et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Mov Disord 2011, 26:2422-2427.
46. Rodrigues C.E., Bonfa E., Caleiro M.T., et al. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res (Hoboken) 2012, 64:1576-1583.
47. Urbanus R.T., Siegerink B., Roest M., et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009, 8:998-1005.
48. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2008, 69:20-28.
49. Seshasai S.R., Wijesuriya S., Sivakumaran R., et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:209-216.
50. Finazzi G. Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No. Intern Emerg Med 2008, 3:197-200.
51. Barbhaiya M., Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr Rheumatol Rep 2011, 13:59-69.